Tinnitus
Conditions
Brief summary
Difference in change of the Tinnitus Handicap Inventory (THI) score from baseline to week 18 between the active treatment and the placebo
Detailed description
Difference in change of headache score using the Visual Analog Scale (VAS) from baseline to week 18 between the active treatment and the placebo, Difference in change of jaw muscle pain score using the VAS from baseline to week 18 between the active treatment and the placebo, Difference in change of QoL score using EQ-5D-5L questionnaire from baseline to week 18 between the active treatment and the placebo
Interventions
Sponsors
Sorlandsklinikken
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference in change of the Tinnitus Handicap Inventory (THI) score from baseline to week 18 between the active treatment and the placebo | — |
Secondary
| Measure | Time frame |
|---|---|
| Difference in change of headache score using the Visual Analog Scale (VAS) from baseline to week 18 between the active treatment and the placebo, Difference in change of jaw muscle pain score using the VAS from baseline to week 18 between the active treatment and the placebo, Difference in change of QoL score using EQ-5D-5L questionnaire from baseline to week 18 between the active treatment and the placebo | — |
Countries
Norway
Outcome results
None listed